Collegium Pharmaceutical (COLL) Non-Current Assets (2014 - 2026)

Collegium Pharmaceutical's Non-Current Assets history runs 13 years deep, the most recent figure standing at $906.3 million for Q1 2026.

• On a quarterly basis, Non-Current Assets fell 17.9% year-over-year to $906.3 million in Q1 2026; TTM through Mar 2026 was $3.9 billion, a 2.76% decrease from a year earlier, with the FY2025 full-year figure at $965.4 million, down 18.28% from the prior year.
• Non-Current Assets declined to $906.3 million in Q1 2026 per COLL's latest filing, from $965.4 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $1.2 billion in Q3 2024 and bottomed at $543.2 million in Q2 2024.
• The 5-year median for Non-Current Assets is $835.8 million (2022), against an average of $847.7 million.
• Across the five-year window, Non-Current Assets surged 152.32% in 2022 and fell 19.72% in 2024, its largest moves.
• Year by year, Non-Current Assets stood at $754.1 million in 2022, then retreated by 19.68% to $605.7 million in 2023, then surged by 95.03% to $1.2 billion in 2024, then decreased by 18.28% to $965.4 million in 2025, then decreased by 6.13% to $906.3 million in 2026.
• Per Business Quant, the three latest COLL Non-Current Assets figures stand at $906.3 million (Q1 2026), $965.4 million (Q4 2025), and $993.5 million (Q3 2025).